Kestra Advisory Services LLC Sells 11,583 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Kestra Advisory Services LLC reduced its holdings in Gilead Sciences by 13.4%, selling 11,583 shares to end the first quarter with 75,051 shares worth approximately $8.4 million.
• Insider trading activity revealed that CEO Daniel Patrick O'day and another insider sold a combined total of 38,000 shares in July and August, resulting in a decrease in their share positions.
• Gilead Sciences reported a quarterly earnings per share (EPS) of $2.01, exceeding analyst expectations, and maintained a revenue growth of 1.4% year-over-year.

Kestra Advisory Services LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,051 shares of the biopharmaceutical company's stock after selling 11,583 shares during the period. Kestra Advisory Services LLC's holdings in Gilead Sciences were worth $8,409,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter valued at $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors boosted its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares in the last quarter. Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares in the last quarter. Finally, IMA Advisory Services Inc. bought a new position in Gilead Sciences during the 1st quarter valued at $39,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,339,230 over the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 1.2%

NASDAQ GILD traded down $1.36 during trading on Thursday, hitting $112.56. 4,145,892 shares of the company traded hands, compared to its average volume of 8,193,325. Gilead Sciences, Inc. has a 12 month low of $77.74 and a 12 month high of $121.83. The business has a fifty day simple moving average of $112.83 and a 200 day simple moving average of $109.35. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $139.67 billion, a P/E ratio of 22.42, a PEG ratio of 0.70 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.